Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Consolidation with Carfilzomib, Lenalidomide and Dexamethasone (KRd) Following ASCT Results in High Rates of Minimal Residual Disease Negativity and Improves Bone Metabolism, in the Absence of Bisphosphonates, Among Newly Diagnosed Patients with Multiple Myeloma

Maria Gavriatopoulou, MD, Evangelos Terpos, MD PhD, Ioannis Ntanasis-Stathopoulos, MD, Panagiotis Malandrakis, MD, Evangelos Eleutherakis-Papaiakovou, MD, Athanasios Papatheodorou, PhD, Nikolaos Kanellias, MD, Magdalini Migkou, MD, Despina Fotiou, MD, Ioanna Dialoupi, MD, Maria Roussou, MD, Nikoletta-Aikaterini Kokkali, Eftathios Kastritis, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 3118.

https://doi.org/10.1182/blood-2019-123916

Published: 2019

Journal Articles

Phase 2 Study of Carfilzomib and Bone Metabolism in Patients with Relapsed Multiple Myeloma

Attaya Suvannasankha, MD, Rafat Abonour, MD, Sherif Farag, MD PhD, Rebecca W. Silbermann, MD, Sariya Wongsaengsak, MD, Mary Helen Cangany, RN, Anita Rush-Taylor, RN, Mark Tann, MD, Sandra K Althouse, PhD, Susan M Perkins, PhD, G David Roodman, MD PhD

Blood (2017) 130 (Supplement 1): 1826.

https://doi.org/10.1182/blood.V130.Suppl_1.1826.1826

Published: 2017

Journal Articles

Factor IX-Deficient Mice Have Decreased Skeletal Health

Emily A Larson, Jason A Taylor, MD PhD

Blood (2016) 128 (22): 559.

https://doi.org/10.1182/blood.V128.22.559.559

Published: 2016

Journal Articles

The Combination of Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT, in the Absence of Dexamethasone and Bisphosphonates, Improves Response Rates and Bone Metabolism in Newly Diagnosed Patients with Multiple Myeloma

Evangelos Terpos, Efstathios Kastritis, MD, Dimitrios Christoulas, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Despoina Kalapanida, Marios Bakogeorgos, Maria Roussou, Meletios A. Dimopoulos

Blood (2014) 124 (21): 3462.

https://doi.org/10.1182/blood.V124.21.3462.3462

Published: 2014

Journal Articles

Early Changes in Cytokines, Chemokines and Indices of Bone Metabolism in a Phase 2 Study of the Bruton Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM)

Ravi Vij, MD, Betty Y. Chang, PhD, Jesus G. Berdeja, MD, Carol Ann Huff, M.D., Nikoletta Lendvai, MD PhD, Yu-Tzu Tai, PhD, Stella Chang, Davina Moussa, Joseph J. Buggy, PhD, Laurence Elias, MD, Paul G. Richardson, MD

Blood (2012) 120 (21): 4039.

https://doi.org/10.1182/blood.V120.21.4039.4039

Published: 2012

Journal Articles

Adenosine Regulates Bone Metabolism Via A 1 , A 2A and A 2B Receptors in Bone Marrow Cells From Normal and Patients with Multiple Myeloma

Wenjie He, Ph.D., Jeesun Park, B.A., Amitabha Mazumder, M.D., Bruce Cronstein, M.D.

Blood (2012) 120 (21): 4977.

https://doi.org/10.1182/blood.V120.21.4977.4977

Published: 2012

Journal Articles

Effects of the Second Generation Tyrosin Kinase Inhibitors on Osteogenic Differentiation.

Daniele Tibullo, Ignazio Barbagallo, Cesarina Giallongo, Piera La Cava, PhD, Antonio Branca, Concetta Conticello, MD, Fabio Stagno, MD, Annalisa Chiarenza, MD, Giuseppe A Palumbo, MD, Francesco Di Raimondo

Blood (2010) 116 (21): 3386.

https://doi.org/10.1182/blood.V116.21.3386.3386

Published: 2010

Journal Articles

Myeloma Cell Interaction with Osteoclasts and Mesenchymal Stem Cells Reveals Genes Associated with Post Relapse Survival

Igor Entin, PhD, Shmuel Yaccoby, PhD, Wen Zhining, John Shaughnessy, Jr., PhD, Bart Barlogie, MD, PhD, Joshua Epstein, DSc

Blood (2010) 116 (21): 2957.

https://doi.org/10.1182/blood.V116.21.2957.2957

Published: 2010

Journal Articles

The Effect of Bortezomib On Bone Metabolism of Patients with Multiple Myeloma: a Korean Multicenter Prospective Study.

Chang-Ki Min, MD, Seok Jin Kim, MD, Je-Jung Lee, MD, Cheolwon Suh, MD, Jin Seok Kim, MD, Sung-Soo Yoon, MD, Byung Soo Kim, MD, Hye Jin Kang, MD, Young Jin Choi, MD, Cheol Soo Kim, MD, Yang Soo Kim, MD, Jae-Yong Kwak, MD, Yoo Jin Kim, MD, Young Don Joo, MD, Yeung-Chul Mun, MD, Deog Yeon Jo, MD, Joon Seong Park, MD, Chi-Young Park, MD, Sung Hyun Kim, MD

Blood (2009) 114 (22): 4871.

https://doi.org/10.1182/blood.V114.22.4871.4871

Published: 2009

Journal Articles

Novel Deuterated Gemini-Vitamin D 3 Analogs Have Potent Antitumor Activity.

Ryoko Okamoto, PhD, Tsuyako Saito, M.D., Talin Haritunians, Ph.D., James O’Kelly, Ph.D., Milan Uskokovic, Ph.D., H. Phillip Koeffler, M.D.

Blood (2007) 110 (11): 4210.

https://doi.org/10.1182/blood.V110.11.4210.4210

Published: 2007

Journal Articles

Bone Metabolism and Endocrine Function in Children with Chronic Myeloid Leukemia (CML) Treated with Imatinib during Puberty.

Fiorina Giona, MD, Stefania Mariani, MD, Annalisa De Vellis, MD, Maria Luisa Moleti, MD, Anna Maria Testi, MD, Mariella D’Angiò, MD, Bruna De Masi, MD, Robert Foa, MD, Lucio Gnessi, MD

Blood (2007) 110 (11): 2942.

https://doi.org/10.1182/blood.V110.11.2942.2942

Published: 2007

Journal Articles

Genomics Analysis of Freshly-Purified Human Marrow Stromal Cells (MSCs): Comparison with Hematopoietic Lineage Cells and Culture-Expanded MSCs.

Elena A. Jones, PhD, Sally E. Kinsey, MD, Anne English, FIBMS, Sarah Field, BSc, Andy Rawstron, PhD, Richard A. Jones, PhD, Liz Strazsynski, BSc, Stephen Rundlett, PhD, Selina Jain, Robert Deans, PhD, Paul Emery, MD, Frederique Ponchel, PhD, Dennis McGonagle, PhD

Blood (2006) 108 (11): 2570.

https://doi.org/10.1182/blood.V108.11.2570.2570

Published: 2006

Journal Articles

Prognostic Significance of Biochemical Markers of Bone Metabolism in Patients with Bone Lesions from Multiple Myeloma (MM).

Richard J. Cook, Robert E. Coleman, Pierre Major, Allan Lipton, Janet E. Brown, Ker-Ai Lee, Matthew Smith, Fred Saad, YinMiao Chen, Yong Jiang Hei

Blood (2005) 106 (11): 5015.

https://doi.org/10.1182/blood.V106.11.5015.5015

Published: 2005

Journal Articles

Changes in Bone Metabolism Induced by Short-Term Treatment with G-CSF for the Mobilization of Allogeneic Hematopoietic Progenitor Cells.

Frank P. Kroschinsky, MD, Sybille Bergmann, Kirsten Poppe-Thiede, MD, Gabriele Siegert, Claudia Rutt, Gerhard Ehninger

Blood (2005) 106 (11): 1772.

https://doi.org/10.1182/blood.V106.11.1772.1772

Published: 2005

Journal Articles

Clinical Evaluation of Bone Mineral Density (BMD) and Bone Metabolism in Hereditary Hemochromatosis (HH).

Yu Ying Yau, Charles D. Bolan, Stacey A. Cecco, Nadja N. Rehak, Michael Collins, James Reynolds, Susan F. Leitman

Blood (2005) 106 (11): 3727.

https://doi.org/10.1182/blood.V106.11.3727.3727

Published: 2005

Journal Articles

Altered Bone and Mineral Metabolism in Patients Treated with Imatinb.

Ellin Berman, MD, Maria Nicolaides, MD, Nicolas Sauter, MD, Suzanne Chanel, RN, Brianne Wilson, Martin Fleisher, PhD

Blood (2004) 104 (11): 4668.

https://doi.org/10.1182/blood.V104.11.4668.4668

Published: 2004

NARROW

Consolidation with Carfilzomib, Lenalidomide and Dexamethasone (KRd) Following ASCT Results in High Rates of Minimal Residual Disease Negativity and Improves Bone Metabolism, in the Absence of Bisphosphonates, Among Newly Diagnosed Patients with Multiple Myeloma

Phase 2 Study of Carfilzomib and Bone Metabolism in Patients with Relapsed Multiple Myeloma

Factor IX-Deficient Mice Have Decreased Skeletal Health

The Combination of Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT, in the Absence of Dexamethasone and Bisphosphonates, Improves Response Rates and Bone Metabolism in Newly Diagnosed Patients with Multiple Myeloma

Early Changes in Cytokines, Chemokines and Indices of Bone Metabolism in a Phase 2 Study of the Bruton Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM)

Adenosine Regulates Bone Metabolism Via A 1 , A 2A and A 2B Receptors in Bone Marrow Cells From Normal and Patients with Multiple Myeloma

Effects of the Second Generation Tyrosin Kinase Inhibitors on Osteogenic Differentiation.

Myeloma Cell Interaction with Osteoclasts and Mesenchymal Stem Cells Reveals Genes Associated with Post Relapse Survival

The Effect of Bortezomib On Bone Metabolism of Patients with Multiple Myeloma: a Korean Multicenter Prospective Study.

Novel Deuterated Gemini-Vitamin D 3 Analogs Have Potent Antitumor Activity.

Bone Metabolism and Endocrine Function in Children with Chronic Myeloid Leukemia (CML) Treated with Imatinib during Puberty.

Genomics Analysis of Freshly-Purified Human Marrow Stromal Cells (MSCs): Comparison with Hematopoietic Lineage Cells and Culture-Expanded MSCs.

Prognostic Significance of Biochemical Markers of Bone Metabolism in Patients with Bone Lesions from Multiple Myeloma (MM).

Changes in Bone Metabolism Induced by Short-Term Treatment with G-CSF for the Mobilization of Allogeneic Hematopoietic Progenitor Cells.

Clinical Evaluation of Bone Mineral Density (BMD) and Bone Metabolism in Hereditary Hemochromatosis (HH).

Altered Bone and Mineral Metabolism in Patients Treated with Imatinb.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only